



UNIVERSITY OF LEEDS

This is a repository copy of *Investigating cancer symptoms in older people: what are the issues and where is the evidence?*.

White Rose Research Online URL for this paper:
<https://eprints.whiterose.ac.uk/163551/>

Version: Accepted Version

Article:

Jones, D orcid.org/0000-0003-3833-6055, di Martino, E, Hatton, NL et al. (3 more authors) (2020) Investigating cancer symptoms in older people: what are the issues and where is the evidence? *British Journal of General Practice*, 70 (696). pp. 321-322. ISSN 0960-1643

<https://doi.org/10.3399/bjgp20x710789>

© British Journal of General Practice 2020. This is an author produced version of an article published in *British Journal of General Practice*. Uploaded in accordance with the publisher's self-archiving policy.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Investigating cancer symptoms in older people – what are the issues and where is the evidence?

Daniel Jones, Erica di Martino, N Luke Hatton, Claire Surr, Niek de Wit, Richard D Neal

Author details:

Daniel Jones MRCGP PhD
Academic Clinical Lecturer in primary care
Leeds Institute of Health Sciences
University of Leeds
Worsley Building
Clarendon Way
Leeds LS2 9NL
d.j.jones@leeds.ac.uk

Erica di Martino PhD
Research Fellow
Leeds Institute of Health Sciences
University of Leeds
Worsley Building
Clarendon Way
Leeds, LS2 9NL
e.dimartino@leeds.ac.uk

Nathaniel Luke Hatton MBCHB
Academic Trust Grade Doctor
Acute and Elderly Medicine
Leeds Teaching Hospital Trust
St James University Hospital Beckett Street
Leeds LS9 7TF
nathaniel.hatton@nhs.net

Claire Surr
Professor of Dementia Studies
Director of the Centre for Dementia Research
School of Health and Community Studies
Leeds Beckett University
Calverley CL521 City Campus
Leeds
LS1 3HE
c.a.surr@leedsbeckett.ac.uk

Niek de Wit GP PhD
Professor of General Practice
Julius Center for Health Sciences and Primary Care
University Medical Center
Utrecht
The Netherlands
n.j.dewit@umcutrecht.nl

Richard D Neal FRCGP PhD

Professor of Primary Care Oncology
Leeds Institute of Health Sciences
University of Leeds
Worsley Building
Clarendon Way
Leeds LS2 9NL
0113 343 6905
r.d.neal@leeds.ac.uk

Introduction

Some may argue that when an older person presents to primary care with symptoms which may represent cancer, they should not be investigated differently from younger patients. We think that cancer risk management in older people requires a different, more personalised approach. Recently there has been a significant increase in knowledge regarding the management of possible cancer symptoms in primary care (1). This knowledge however, is not age related, and research on the specific diagnostic management of symptomatic older people is scarce, despite older age being associated with greater likelihood of developing cancer. This editorial will explore the issues that are specific to the management of older people with a potential cancer diagnosis, identifying gaps in our knowledge base and highlighting the need for more research to underpin good practice.

Current evidence and best practice

The National Institute for Health and Care Excellence (NICE) released guidelines in 2015 on the recognition and referral of suspected cancer in primary care. While the guideline provides lower age limits for investigation and referral of specific symptoms it has no upper age limits, it does not specifically discuss older age when recommending investigation or referral, nor does it consider frailty, quality of life or comorbidities. The guidance recommends discussing patients' preferences about investigations and their potential risks and benefits, but states that there is no evidence on the information needs of older people. In fact, older people are significantly underrepresented in the evidence base underpinning the NICE guidelines. If colorectal cancer is taken as an example of a cancer with a peak incidence in 85-89 year olds, the guidance is based on 31 studies. In five of these studies older patients were specifically excluded. For the other studies, where data were available, the average age of the patients was significantly lower than the average age of colorectal cancer diagnosis in the UK.

Increasing age, increasing frailty and increasing cancer risk

Ageing is a very individual process and from a health perspective there is no 'typical' older person. However, for research and administration purposes 'older adults' are arbitrarily defined as individuals aged 65 years and older. With the rise in life expectancy, the ages and profile of adults included in this age category is widening. Cancer is a disease of older people with cancer incidence rates in the UK peaking at 85-89 years old and worldwide cancer incidence rates increasing most rapidly in the over 70 age group (see figures 1 and 2) (2, 3). In the UK, most cancers are diagnosed following symptomatic presentation to primary care. This is particularly true in those aged 75 and over who are not routinely screened for cancer due to upper age limits in the national screening programmes. It is established that older people have a lower awareness of potential cancer symptoms, and a lack of awareness that increasing age is a risk factor for cancer (4). The time from first presentation with symptoms in general practice to a diagnosis of cancer increases with age (5), and older patients are less likely to be referred on a two week wait (2ww) cancer referral, yet are

much more likely to be diagnosed with cancer when a 2ww referral is sent. General practitioners face a challenge, managing the increasing numbers of older patients with a potential diagnosis of cancer, often with a poor prognosis, with little scientific evidence to guide decisions.

Older patients have increased risks

In most patients, early stage diagnosis is important and is associated with improved survival (6). However, in older people potential survival benefits are shorter due to natural life expectancy and older cancer survivors have increased needs, reporting more multimorbidity and poorer health outcomes (7). The incidence of frailty increases significantly with age, as does the incidence of morbidity and mortality, resulting from invasive investigations and cancer treatment in frail patients (8). The imperative to diagnose cancer early must therefore be balanced with the preferences of older and frail patients. A systematic review found that older age was linked with a preference for quality of life rather than length of life (9). Furthermore, patients over 70 have been shown to be less likely to want investigations for possible cancer symptoms and to accept a higher risk of cancer being undiagnosed (10). Older people want to be able to do the things they consider important for as long as possible, therefore any investigation, referral or treatment should “add life to years, not years to life”(11). However, in some individuals even a marginal gain in life expectancy could be important, enabling the patient to attend a family wedding, or meet a new-born grandchild for example. An additional consideration is that investigations for cancer are rarely available in the community and often require more than one visit to hospital. This may be particularly challenging for frail older people, particularly those living in care homes or who have limited family networks to support attendance at hospital appointments.

Difficult decisions, balancing needs, and informing decisions

GPs will increasingly encounter older people who present with symptoms which could be due to cancer. The decision on whether and when, to investigate or to refer these patients is complex and should take into account the patient’s preferences and in some cases those of their family. When discussing this decision with patients, there is a need to consider issues such as the patient’s quality of life, comorbidities and degree of frailty and how potential investigations may impact on these factors. The value to patients of having a diagnosis should be considered, and how a diagnosis may provide better access to palliative care, specialist nurses and charitable support which may improve symptomatic management and quality of life (12). Referral for suspected cancer symptoms by GPs initiates a diagnostic pathway in secondary care which may escalate from simple to more invasive investigations, followed by biopsies and treatment. However, as after the start of the pathway, continuation is rarely discussed, it is the GP who plays a crucial role in explaining the pros and cons of the initial diagnostic referral.

Whilst frailty is increasing, there remains a significant proportion of older people who are healthy and do benefit from a timely cancer diagnosis. Therefore, guidance that considers age as a strict cut-off point is ethically unjust and is unlikely to be helpful in defining new care pathways for the heterogeneous banner of ‘older people’. What is needed is shared decision making (SDM) with patients after evaluating the pros and cons of diagnostic referral on an individual basis (11). SDM is a key part of health policy in the UK with the most recent NHS Long Term Plan advocating personalised care across the entire health and care system. This may be particularly challenging in older people, as research demonstrates that they may be less willing to actively participate in medical decisions. Other barriers to SDM include a lack of GP time and patient comorbidities such as dementia, or stroke which may impact on understanding, communication and decision-making abilities. However, SDM should be encouraged with older patients and this shared care should

continue after the initial decision, through cancer investigations and treatment, ongoing monitoring and palliative care.

Specific research is needed for older people

Currently GPs use their own judgement to make difficult decisions around referral for cancer diagnosis, and use generic, not age specific guidelines to support them. NICE guidelines advocate referral regardless of age or frailty, leading to potential harm from over investigation and over diagnosis without any clinical benefit. The guideline introduced the concept of cancer risk, suggesting that patients with a risk of 3% or greater be referred for further investigation. Cancer risk increases with age, as does the risk that an 'alarm' symptom may be due to cancer, as a result a greater proportion of older people will have a cancer risk greater than 3%. However, it may be relevant to reconsider the definition of adequate and timely diagnosis and treatment of cancer, given the impact of comorbidity, physical and mental decline on life expectancy, and preferences of older people for accessing diagnostic and therapeutic interventions. To inform and improve care, more research is urgently needed on frail older patients and their carers' thoughts on, and experiences of, investigation and referral for cancer. This will support greater understanding of the risks and benefits of a cancer diagnosis for older people with frailty or comorbidity and improve informed shared decision making with older people.

1. Hamilton W, Walter FM, Rubin G, Neal RD. *Improving early diagnosis of symptomatic cancer*. *Nat Rev Clin Oncol*. (2016) **13**(12):740-9.
2. Institute for Health Metrics and Evaluation. *Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017*. Seattle: 2018.
3. Cancer Research UK. *Cancer statistics*. (2018).
4. Forbes LJ, Simon AE, Warburton F, Boniface D, Brain KE, Dessaix A, et al. *Differences in cancer awareness and beliefs between Australia, Canada, Denmark, Norway, Sweden and the UK (the International Cancer Benchmarking Partnership): do they contribute to differences in cancer survival?* *Br J Cancer*. (2013) **108**(2):292-300.
5. Din NU, Ukoumunne OC, Rubin G, Hamilton W, Carter B, Stapley S, et al. *Age and Gender Variations in Cancer Diagnostic Intervals in 15 Cancers: Analysis of Data from the UK Clinical Practice Research Datalink*. *Plos One*. (2015) **10**(5):e0127717.
6. Neal RD, Tharmanathan P, France B, Din NU, Cotton S, Fallon-Ferguson J, et al. *Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review*. *Br J Cancer*. (2015) **112 Suppl 1**:S92-107.
7. Warner DF, Schiltz NK, Stange KC, Given CW, Owusu C, Berger NA, et al. *Complex multimorbidity and health outcomes in older adult cancer survivors*. *Fam Med Community Health*. (2017) **5**(2):129-38.
8. Handforth C, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ, et al. *The prevalence and outcomes of frailty in older cancer patients: a systematic review*. *Ann Oncol*. (2015) **26**(6):1091-101.
9. Shrestha A, Martin C, Walters S, Collins K, Burton M, Wyld L. *Quality of life versus Length of Life Considerations in Cancer Patients: A Systematic Literature Review*. *Psycho-Oncology*. (2019).
10. Banks J, Hollinghurst S, Bigwood L, Peters TJ, Walter FM, Hamilton W. *Preferences for cancer investigation: a vignette-based study of primary-care attendees*. *The Lancet Oncology*. (2014) **15**(2):232-40.
11. de Wit NJ, Schuurmans MJ. *Future care for older people in general practice: paradigm shifts are needed*. *Br J Gen Pract*. (2017) **67**(664):500-1.
12. Croft P, Altman DG, Deeks JJ, Dunn KM, Hay AD, Hemingway H, et al. *The science of clinical practice: disease diagnosis or patient prognosis? Evidence about "what is likely to happen" should shape clinical practice*. *BMC Med*. (2015) **13**:20.

EdM is funded by the multi-institutional CanTest Collaborative, which is funded by Cancer Research UK (C8640/A23385), of which RDN is an Associate Director and NdW is a member of senior faculty.

Figure 1

Cancer Research UK. *Cancer statistics*. (2018)

<https://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/age>





Figure 2

Our world in data, using stats from Institute for Health Metrics and Evaluation. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017. Seattle: 2018.

<https://ourworldindata.org/cancer#cancer-prevalence-by-age>

Number of people with cancer by age, World

Total number of people with cancer, differentiated by age. This is measured across all cancer types.



Source: IHME, Global Burden of Disease

CC BY